An anti-ANGPTL3/8 antibody decreases circulating triglycerides by binding to a LPL-inhibitory leucine zipper-like motif.

Autor: Balasubramaniam D; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA., Schroeder O; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA., Russell AM; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA., Fitchett JR; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA., Austin AK; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA., Beyer TP; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA., Chen YQ; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA., Day JW; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA., Ehsani M; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA., Heng AR; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA., Zhen EY; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA., Davies J; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA., Glaesner W; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA., Jones BE; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA., Siegel RW; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA., Qian YW; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA., Konrad RJ; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA. Electronic address: konrad_robert@lilly.com.

Publikováno v: Journal of lipid research [J Lipid Res] 2022 May; Vol. 63 (5), pp. 100198. Date of Electronic Publication: 2022 Mar 17.

Low incidence of anti-drug antibodies in patients with type 2 diabetes treated with once-weekly glucagon-like peptide-1 receptor agonist dulaglutide.

Autor: Milicevic, Z., Anglin, G., Harper, K., Konrad, R. J., Skrivanek, Z., Glaesner, W., Karanikas, C. A., Mace, K.

Publikováno v: Diabetes, Obesity & Metabolism; May2016, Vol. 18 Issue 5, p533-536, 4p

A pharmacokinetic study comparing the biosimilar HEC14028 and Dulaglutide (Trulicity®) in healthy Chinese subjects.

Autor: Gao, Xianglei¹ (AUTHOR), Di, Yujing² (AUTHOR), Lv, Yuan¹ (AUTHOR), Luan, Yingcai² (AUTHOR), Xiong, Yang¹ (AUTHOR), Xu, Yuli¹ (AUTHOR), Li, Yusheng¹ (AUTHOR), Guo, Linfeng¹ (AUTHOR), Li, Xiaoping¹ (AUTHOR), Deng, Li¹ (AUTHOR), Zhuang, Yulei¹ (AUTHOR), Hou, Jie² (AUTHOR) jie.hou@gohealtharo.com

Publikováno v: CTS: Clinical & Translational Science. Apr2024, Vol. 17 Issue 4, p1-11. 11p.

Molecular Insights into Fully Human and Humanized Monoclonal Antibodies: What are the Differences and Should Dermatologists Care?

Autor: Mallbris L; Eli Lilly and Company, Indianapolis, Indiana., Davies J; Eli Lilly and Company, Indianapolis, Indiana., Glasebrook A; Eli Lilly and Company, Indianapolis, Indiana., Tang Y; Eli Lilly and Company, Indianapolis, Indiana., Glaesner W; Eli Lilly and Company, Indianapolis, Indiana., Nickoloff BJ; Eli Lilly and Company, Indianapolis, Indiana.

Publikováno v: The Journal of clinical and aesthetic dermatology [J Clin Aesthet Dermatol] 2016 Jul; Vol. 9 (7), pp. 13-5. Date of Electronic Publication: 2016 Jul 01.

[Pharmacological profile and clinical trial results of a long-acting, once weekly human GLP-1 receptor agonist Dulaglutide (Genetical Recombination)].

Autor: Tamaki C, Takeuchi M, Iwamoto N, Glaesner W

Publikováno v: Nihon yakurigaku zasshi. Folia pharmacologica Japonica [Nihon Yakurigaku Zasshi] 2015 Oct; Vol. 146 (4), pp. 215-24.